# Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of Lamellar Ichthyosis

> **NCT00282724** · PHASE2,PHASE3 · COMPLETED · sponsor: **Stiefel, a GSK Company** · enrollment: 98 (actual)

## Conditions studied

- Ichthyosis, Lamellar

## Interventions

- **DRUG:** Liarozole

## Key facts

- **NCT ID:** NCT00282724
- **Lead sponsor:** Stiefel, a GSK Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2011-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00282724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00282724, "Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of Lamellar Ichthyosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00282724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*